dermatology paediatrics

POEM — Patient-Oriented Eczema Measure

7-item patient/parent-reported atopic eczema symptom score (Charman 2004). Each item 0–4 (days in past week). Total 0–28. Recommended core outcome by HOME initiative.

Q1. Itchy skin — number of days in past week*

Q2. Disturbed sleep because of eczema — number of days in past week*

Q3. Bleeding skin — number of days in past week*

Q4. Skin weeping or oozing clear fluid — number of days in past week*

Q5. Cracked skin — number of days in past week*

Q6. Flaking skin — number of days in past week*

Q7. Dry or rough skin — number of days in past week*

References

Curated clinical cross-links plus same-class fallbacks.

Drugs

Tralokinumab · IL-13 Inhibitor — Atopic Eczema
Abrocitinib · JAK1 Inhibitor — Atopic Eczema
Lebrikizumab · IL-13 Inhibitor — Atopic Eczema
Baricitinib 2–4mg (Atopic Dermatitis / Alopecia Areata) · JAK inhibitor (JAK1/JAK2) — systemic immunosuppressant
Ciclosporin · Systemic Immunosuppressant — Eczema / Psoriasis
Azathioprine · Systemic Immunosuppressant — Eczema / Autoimmune Dermatoses

Pathways

Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
Cellulitis and Erysipelas · NICE NG141 2019 / CREST
Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD

Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.

References

Related